Head to Head Contrast: Alkermes (ALKS) vs. Its Rivals

Alkermes (NASDAQ:ALKS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Alkermes to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Institutional & Insider Ownership

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alkermes	$1.48 billion	$241.66 million	-2,351.50
Alkermes Competitors	$702.34 million	$9.48 million	-18.76

Alkermes has higher revenue and earnings than its peers. Alkermes is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alkermes and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	-0.02%	0.40%	0.19%
Alkermes Competitors	-12,323.33%	-195.91%	-30.60%

Risk and Volatility

Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Alkermes’ peers have a beta of -1.82, meaning that their average stock price is 282% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Alkermes and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	5	10	1	2.65
Alkermes Competitors	9874	15295	45659	1600	2.54

Alkermes presently has a consensus target price of $55.73, suggesting a potential upside of 18.51%. As a group, “Biotechnology” companies have a potential upside of 126.54%. Given Alkermes’ peers higher possible upside, analysts clearly believe Alkermes has less favorable growth aspects than its peers.

Summary

Alkermes beats its peers on 9 of the 13 factors compared.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.